13544-44-0

Basic information

• Product Name: 2, 4-DICHLORO-5-IODOPYRIMIDINE
• Synonyms: 5-Iodo-2,4-dichloropyrimidine;2,4-Dichloro-5-iodopyrimidine;2,4-Dichloro-5-iodo-1,3-diazine;2,4-Dichloro-5-iodopyriMidine, 95+%;Pyrimidine, 2,4-dichloro-5-iodo-;2,4-Dichloro-5-iodopyrimidine 95%
• CAS NO: 13544-44-0
• Molecular Formula: C₄HCl₂IN₂
• Molecular Weight: 274.87
• EINECS: 1312995-182-4
• Product Categories: Pyrimidine series;pharmacetical;Organohalides;Pyrimidine;Pyrimidines;Halides;Pyrazines, Pyrimidines & Pyridazines;Heterocycle-Pyrimidine series
• Mol File: 13544-44-0.mol
• Article Data: 8

Chemical Properties

• Melting Point: 68.0 to 72.0 °C
• Boiling Point: 310.2 °C at 760 mmHg
• Flash Point: 141.4 °C
• Appearance: /
• Density: 2.255 g/cm³
• Vapor Pressure: 0.00111mmHg at 25°C
• Refractive Index: 1.662
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: soluble in Methanol
• PKA: -4.19±0.29(Predicted)
• CAS DataBase Reference: 2, 4-DICHLORO-5-IODOPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2, 4-DICHLORO-5-IODOPYRIMIDINE(13544-44-0)
• EPA Substance Registry System: 2, 4-DICHLORO-5-IODOPYRIMIDINE(13544-44-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• RIDADR: 2811
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: Ⅲ
• Hazardous Substances Data: 13544-44-0(Hazardous Substances Data)

Usage

Chemical Properties

Off-white powder

InChI:InChI=1/C4HCl2IN2/c5-3-2(7)1-8-4(6)9-3/h1H

Upstream product

• 696-07-1 5-iodo-2,4-pyrimidine-diol 
• 696-07-1 5-iodouracil 

Downstream Products

• 749860-50-2 C₁₁H₇ClF₂IN₃ 
• 52522-99-3 2,4-dimethoxy-5-iodopyrimidine 
• 3932-97-6 2,4-dichloro-5-trifluoromethylpyrimidine 
• 871254-61-4 2,4-dichloro-5-pyrimidinecarboxaldehyde 
• 1439394-87-2 tert-butyl 1-(4-(2-chloro-5-iodopyrimidin-4-ylamino)phenyl)cyclobutylcarbamate 
• 1425044-57-0 (S)-3-(1-((2-chloro-5-iodopyrimidin-4-yl)amino)ethyl)-8-(2-methoxypyrimidin-5-yl)-2-phenylisoquinolin-1(2H)-one 
• 1223498-47-2 4-{[(1R,2R)-2-(benzyloxy)-1-methylpropyl]oxy}-2-chloro-5-iodopyrimidine 
• 1273561-17-3 C₂₀H₂₄ClIN₄O₄ 

Relevant articles and documents

Method for preparing 5-trifluoromethyl uracil

The invention belongs to the field of organic synthesis, and specifically relates to a method for preparing 5-trifluoromethyl uracil. The method comprises the following steps: firstly, carrying out chlorination reaction on 5-iodouracil and phosphorus oxychloride, thus obtaining 2,4-dichloro-5-iodopyrimidine; secondly, carrying out trifluoromethylation reaction on the 2,4-dichloro-5-iodopyrimidineand a trifluoromethylating reagent, thus obtaining 2,4-dichloro-5-trifluoromethylpyrimidine; finally, enabling the 2,4-dichloro-5-trifluoromethylpyrimidine to react with acetic acid, thus obtaining aproduct. According to the method disclosed by the invention, since chlorination reaction, trifluoromethylation reaction and hydrolysis reaction are adopted, a key intermediate-trifluoromethyl uracil of trifluorothymidine is synthesized in high yield, low cost and low pollution.

Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV

The discovery of two classes of heterocyclic dipeptidyl peptidase IV (DPP-4) inhibitors, pyrimidinones and pyrimidinediones, is described. After a single oral dose, these potent, selective, and noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and lowering of blood glucose in animal models of diabetes. Compounds 13a, 27b, and 27j were selected for development.

ALKYNYLPYRIMIDINES AS TIE2 KINASE INHIBITORS

The invention relates to alkynylpyrimidines according to the general formula (I) in which A, R1, R2, R3, R4, R5, and R6 are as defined in the claims, to pharmaceutical compositions comprising said alkynylpyrimidines, to methods of preparing said alkynylpyrimidines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 and VEGFR2 signalling.